Skip to content
Clinical Trials – home
Therapeutic area

Skin and subcutaneous tissue disorders – page 33

  • 844 clinical trials
  • 268 recruiting
  • 353 conditions
  • 25 countries

Conditions in this area

353 conditions with trials, the busiest first

Clinical trials in Skin and subcutaneous tissue disorders

844 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

844 clinical trials

Dermatitis atopic

Not recruiting

A study to evaluate the safety and effectiveness of galvokimig in adults with moderate to severe atopic dermatitis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:UCB Biopharma

Dermatitis atopic

Not recruiting

A Study of KT-621 Tablets Taken by Mouth for Adults with Moderate to Severe Atopic Dermatitis

Investigational
Countries:CzechiaCzechia
  • Participants:0–17 years · 18–64 years · 65+ years
  • Sponsor:Kymera Therapeutics Inc.

Dermatitis acneiform

Not recruiting

A study testing aprepitant gel for treating skin rash in cancer patients receiving epidermal growth factor receptor inhibitor therapy

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Hoth Therapeutics Inc.

Axial spondyloarthritis+2

Not recruiting

A study testing SPY072 compared to placebo in adults with moderately to severely active rheumatologic disease

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:Spyre Therapeutics Inc.

Systemic scleroderma

Not recruiting

A study to test if tibulizumab works and is safe for adults with systemic sclerosis

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:Zura Bio Inc.

Dermatitis atopic

Not recruiting

A study testing BFB759 compared to placebo to evaluate effectiveness and safety in adult patients with atopic dermatitis

Investigational
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Sponsor:Bluefin Biomedicine Inc.

Study of Navenibart to prevent attacks in adults and adolescents with Hereditary Angioedema

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:NAVENIBART
  • Sponsor:Astria Therapeutics Inc.

Psoriasis

Not recruiting

Comparison of zasocitinib and deucravacitinib in adults with moderate to severe plaque psoriasis

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Takeda Development Center Americas Inc.

Psoriasis

Not recruiting

Study of zasocitinib (TAK-279) and apremilast compared to placebo in adults with moderate to severe plaque psoriasis

Registered drug
Countries:BulgariaBulgaria
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Takeda Development Center Americas Inc.

Psoriasis

Not recruiting

Study of TAK-279 and apremilast for adults with moderate to severe plaque psoriasis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Takeda Development Center Americas Inc.

Dermatitis atopic

Not recruiting

Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Investigational
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Dermatitis atopic

Not recruiting

Study of rocatinlimab (AMG 451) in adolescents with moderate to severe atopic dermatitis to evaluate its effectiveness and safety over 52 weeks

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years
  • Sponsor:Amgen Inc.

Substances studied in this area

The therapies tested most often in Skin and subcutaneous tissue disorders trials.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.